Table 1.

Demographic and characteristic of patient with violaceous hue and inactive scleritis

Patient Number	Age/Gender	Affected eye	Type of scleritis	Associated disease	Systemic medications	Topical medications
1	36/F	OD	diffuse	History of treated latent TB	none	PA
2	56/F	OD	nodular	Undifferentiated	MTX 25 mg weekly	none
3	66/F	OS	nodular	GPA/ History of treated latent TB	RTX, Pred 4 mg daily	none
4	58/M	OS	nodular	Undifferentiated	IFX 20 mg/kg q 4 wk, Pred 20 mg daily	Topical NSAID
5	53/F	OS	diffuse	RA	ADA 40 mg q 7 days, Pred 3 mg daily	PA
6	67/F	OS	diffuse	RA	none	none
7	34/F	OS	diffuse	Herpes simplex/ History of treated latent TB	none	none
8	57/F	OS	diffuse	RA	ADA 40 mg q 14 days, MTX 20 mg weekly	FML
9	41/F	OD	diffuse	NXG	IVIG	none

ADA adalimumab, F female, FML  fluoromethalone, GPA granulomatosis with polyangiitis, IFX infliximab, IVIG intravenous immunoglobulin, M male, MTX methotrexate, NXG necrobiotic xanthogranuloma, OD right eye, OS left eye, PA prednisolone acetate, Pred  prednisone, RA  rheumatoid arthritis, RTX rituximab, TB tuberculosis, TCZ tocilizumab